240 related articles for article (PubMed ID: 32679209)
1. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
Skaarup SH; Schmid JM; Skjold T; Graumann O; Hoffmann HJ
J Allergy Clin Immunol; 2021 Mar; 147(3):1011-1019. PubMed ID: 32679209
[TBL] [Abstract][Full Text] [Related]
2. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.
Hylander T; Larsson O; Petersson-Westin U; Eriksson M; Kumlien Georén S; Winqvist O; Cardell LO
Respir Res; 2016 Jan; 17():10. PubMed ID: 26817454
[TBL] [Abstract][Full Text] [Related]
3. A 5-Year Open-Label Follow-up of a Randomized Double-Blind Placebo-Controlled Trial of Intralymphatic Immunotherapy for Birch and Grass Allergy Reveals Long-term Beneficial Effects.
Hjalmarsson E; Hellkvist L; Karlsson A; Winquist O; Kumlien Georén S; Westin U; Cardell LO
J Investig Allergol Clin Immunol; 2023 Oct; 33(5):362-372. PubMed ID: 37843385
[TBL] [Abstract][Full Text] [Related]
4. Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial.
Ahlbeck L; Ahlberg E; Stuivers L; Björkander J; Nyström U; Retsas P; Govindaraj D; Jenmalm MC; Duchén K
Clin Exp Allergy; 2023 Aug; 53(8):809-820. PubMed ID: 37013723
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
[TBL] [Abstract][Full Text] [Related]
7. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
8. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Hylander T; Latif L; Petersson-Westin U; Cardell LO
J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
[TBL] [Abstract][Full Text] [Related]
9. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.
Ellis AK; Frankish CW; O'Hehir RE; Armstrong K; Steacy L; Larché M; Hafner RP
J Allergy Clin Immunol; 2017 Aug; 140(2):486-496. PubMed ID: 28236469
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study.
Leynadier F; Banoun L; Dollois B; Terrier P; Epstein M; Guinnepain MT; Firon D; Traube C; Fadel R; André C
Clin Exp Allergy; 2001 Jul; 31(7):988-96. PubMed ID: 11467988
[TBL] [Abstract][Full Text] [Related]
11. Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial.
Sola Martínez FJ; Barranco Jiménez RM; Martín García C; Senent Sánchez C; Blanco Guerra C; Fernández-Rivas M; Vega Castro A; Dávila González I; Carbonell Martínez A; Panizo Bravo C; Gómez Torrijos E; Rodríguez Gil D; Palacios Peláez R
Clin Exp Allergy; 2020 Dec; 50(12):1352-1361. PubMed ID: 32946612
[TBL] [Abstract][Full Text] [Related]
12. A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol.
Klimek L; Uhlig J; Mösges R; Rettig K; Pfaar O
Allergy; 2014 Dec; 69(12):1629-38. PubMed ID: 25130503
[TBL] [Abstract][Full Text] [Related]
13. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
14. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
15. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.
Mösges R; Bachert C; Panzner P; Calderon MA; Haazen L; Pirotton S; Wathelet N; Durham SR; Bonny MA; Legon T; von Frenckell R; Pfaar O; Shamji MH
Allergy; 2018 Sep; 73(9):1842-1850. PubMed ID: 29512827
[TBL] [Abstract][Full Text] [Related]
16. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis.
Patterson AM; Bonny AE; Shiels WE; Erwin EA
Ann Allergy Asthma Immunol; 2016 Feb; 116(2):168-70. PubMed ID: 26706294
[No Abstract] [Full Text] [Related]
17. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
[TBL] [Abstract][Full Text] [Related]
18. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
19. Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis.
Pfaar O; Lang S; Pieper-Fürst U; Astvatsatourov A; Gerich F; Klimek L; Kramer MF; Reydelet Y; Shah-Hosseini K; Mösges R
Allergy; 2018 Jan; 73(1):187-195. PubMed ID: 28675499
[TBL] [Abstract][Full Text] [Related]
20. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
